email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1951 - 1965
of 3615 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Shenogen Pharma In-licenses Alopexx Fusion CD20 Protein for Lymphoma
$5.00
Available
Innovent Starts China Phase II Trial of FGFR1/2/3 Inhibitor for Cholangiocarcinoma
$5.00
Available
Abpro Bio Announces $1.1 Billion Deal for Asian Rights to Two Abpro Bi-specifics
$5.00
Available
3SBio Contributes to $126 Million MPM/Dana-Farber Fund for Cancer Start-Ups
$5.00
Available
Sihuan Pharma Starts China Trials of Favipiravir to Treat COVID-19
$5.00
Available
Merck Announces China Erbitux Approval for Head and Neck Cancer
$5.00
Available
Harbour BioMed to Begin US Trials of CLTA-4 Antibody
$5.00
Available
MapKure Doses First Patient in Australian Phase I Trial of BeiGene's B-RAF Inhibitor
$5.00
Available
Gilead Starts Two Phase III Trials of Remdesivir for COVID-19
$5.00
Available
Harbour BioMed Approved to Start US Trials of PD-L1 in Orphan Disease
$5.00
Available
Harvard and Guangzhou Institute of Respiratory Health Form $115 Million COVID-19 Collaboration
$5.00
Available
Cyagen Closes $41 Million Series B to Expand Animal Research Model Business
$5.00
Available
Moderna Ships Coronavirus Vaccine for Clinical Trials
$5.00
Available
WuXi Biologics and Vir Biotech Team up to Develop COVID-19 Antibodies
$5.00
Available
CICC Capital Closes $229 Million Fund for China Biologic Investments
$5.00
Available